ABVC Biopharma Inc (ABVC)

ABVC Biopharma Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker ABVC. Based in Fremont, California, the company focuses on developing drugs and medical devices aimed at addressing unmet medical needs in the United States. Its pipeline includes several product candidates in different stages of clinical development. These include ABV-1501 for triple negative breast cancer, ABV-1505 for adult attention deficit hyperactivity disorder, ABV-1702 for myelodysplastic syndromes, ABV-1601 for depression in cancer patients, ABV-1701 Vitargus for retinal detachment or vitreous hemorrhage, ABV-1519 for non-small cell lung cancer, and ABV-1703 for metastatic pancreatic cancer. The company has also developed ABV-1504 for depressive disorders, which has completed Phase II trials, along with ABV-2001, an intraocular irrigation solution, and ABV-2002, a corneal storage solution. ABVC has co-development and collaboration agreements with Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.